WEBVTT 00:00:00.000 --> 00:00:02.120 Welcome to the deep dive. This is where we take 00:00:02.120 --> 00:00:04.440 the sources you send us on a topic you're curious 00:00:04.440 --> 00:00:07.860 about, and we really get into it. Yeah, the idea 00:00:07.860 --> 00:00:10.460 is to pull out the key stuff, maybe some surprising 00:00:10.460 --> 00:00:13.019 facts, and give you a solid handle on the subject, 00:00:13.460 --> 00:00:15.759 you having to read through piles of material 00:00:15.759 --> 00:00:19.140 yourself. Exactly. And today we're diving into 00:00:19.140 --> 00:00:22.079 levofloxacin. You send over a great mix of info, 00:00:22.199 --> 00:00:24.300 and we're going to track this antibiotic from 00:00:24.539 --> 00:00:26.579 Well, it's beginnings right up to where it stands 00:00:26.579 --> 00:00:28.539 now. We'll be looking at how it actually works 00:00:28.539 --> 00:00:32.359 inside the body, how it's manufactured, and definitely 00:00:32.359 --> 00:00:34.039 getting into some of the controversies that have 00:00:34.039 --> 00:00:36.000 topped up around its use over the years. Right. 00:00:36.240 --> 00:00:38.439 Antibiotics are something most of us have probably 00:00:38.439 --> 00:00:40.859 encountered, maybe taken ourselves. But I think 00:00:40.859 --> 00:00:43.740 this look at levofloxacin will go, well, quite 00:00:43.740 --> 00:00:46.039 a bit deeper than just that surface awareness. 00:00:46.380 --> 00:00:48.500 We're talking the science behind it, the development 00:00:48.500 --> 00:00:51.929 path, and a regulatory story that's frankly got 00:00:51.929 --> 00:00:54.369 some pretty significant twists. So yeah, let's 00:00:54.369 --> 00:00:57.409 get started. OK, so antibiotics. It's kind of 00:00:57.409 --> 00:00:59.530 amazing to think that we didn't invent the core 00:00:59.530 --> 00:01:02.240 concept, right? Bacteria have been doing this 00:01:02.240 --> 00:01:04.900 for ages. Oh, billions of years. They've been 00:01:04.900 --> 00:01:06.719 producing these compounds to fight each other. 00:01:06.920 --> 00:01:08.560 We mostly just discovered what they were already 00:01:08.560 --> 00:01:10.920 making and figured out how to use it. And levofloxacin 00:01:10.920 --> 00:01:14.340 fits into that discovery timeline later in the 00:01:14.340 --> 00:01:17.739 20th century, patented in 1987, I see, and then 00:01:17.739 --> 00:01:20.599 got the FDA green light in the US in 96. That's 00:01:20.599 --> 00:01:23.579 right. And that timing puts it in a pretty active 00:01:23.579 --> 00:01:25.760 period for antibiotic development. It's what 00:01:25.760 --> 00:01:28.400 we call a third generation fluoroquinolone. Third 00:01:28.400 --> 00:01:30.659 generation. What does that typically mean in 00:01:30.659 --> 00:01:33.260 antibiotic terms? Better, broader? Usually, yeah. 00:01:33.480 --> 00:01:35.640 It often means improvements over the earlier 00:01:35.640 --> 00:01:38.599 drugs in that same class. Maybe it works against 00:01:38.599 --> 00:01:40.840 a wider range of bacteria, or maybe it's absorbed 00:01:40.840 --> 00:01:42.579 or distributed in the body more effectively, 00:01:42.719 --> 00:01:44.219 that sort of thing. It signals an evolution. 00:01:44.409 --> 00:01:47.049 Interesting. And we even have this level of detail 00:01:47.049 --> 00:01:51.549 from a European patent, EP145 -1194b2. It's about 00:01:51.549 --> 00:01:54.469 making levofloxacin a hemihydrate. Looking at 00:01:54.469 --> 00:01:57.170 the dates and related filings, it really shows 00:01:57.170 --> 00:01:59.890 the technical slog involved. It really does. 00:02:00.430 --> 00:02:02.530 That patent gets into the nitty -gritty chemistry 00:02:02.530 --> 00:02:05.890 needed to get a stable, effective form of the 00:02:05.890 --> 00:02:08.389 drug, the hemihydrate in this case, making sure 00:02:08.389 --> 00:02:10.379 it's consistent and pure. But there was a little 00:02:10.379 --> 00:02:13.280 hiccup with that patent. Yeah, a small administrative 00:02:13.280 --> 00:02:15.400 one, it seems. It actually lapsed in Italy back 00:02:15.400 --> 00:02:18.500 in 2006. Looks like it was potentially due to 00:02:18.500 --> 00:02:22.860 translation issues or maybe unpaid fees. So even 00:02:22.860 --> 00:02:25.780 with groundbreaking science, you still have paperwork 00:02:25.780 --> 00:02:28.139 hurdles. It's a good reminder, isn't it? The 00:02:28.139 --> 00:02:30.099 whole process involves more than just the lab 00:02:30.099 --> 00:02:32.780 work. Regulatory and administrative steps are 00:02:32.780 --> 00:02:35.460 crucial. You wonder if that lapse maybe affected 00:02:35.460 --> 00:02:38.379 costs or availability there early on compared 00:02:38.379 --> 00:02:41.259 to elsewhere. Probably not hugely, but it's possible. 00:02:41.599 --> 00:02:44.000 Okay, so moving from the patent office to the 00:02:44.000 --> 00:02:47.219 pharmacy shelf essentially Where does levofloxacin 00:02:47.219 --> 00:02:50.340 actually get used in medicine? What's it approved 00:02:50.340 --> 00:02:52.900 for? It's got a fairly wide range of FDA approved 00:02:52.900 --> 00:02:55.099 uses that tackle some pretty serious stuff like 00:02:55.099 --> 00:02:56.900 nosocomial pneumonia That's the kind you might 00:02:56.900 --> 00:02:59.740 pick up in a hospital right and also community 00:02:59.740 --> 00:03:02.199 acquired pneumonia the kind you get well out 00:03:02.199 --> 00:03:04.650 in the community OK, those are definitely significant 00:03:04.650 --> 00:03:07.069 lung infections. What else? It's also approved 00:03:07.069 --> 00:03:10.789 for skin and skin structure infections, SSTIs, 00:03:11.330 --> 00:03:13.530 that includes both complicated ones and the more 00:03:13.530 --> 00:03:16.889 straightforward types, and chronic bacterial 00:03:16.889 --> 00:03:19.129 prostatitis, which is a persistent infection 00:03:19.129 --> 00:03:21.550 in the prostate gland. Got it. But I think I 00:03:21.550 --> 00:03:23.370 saw some notes about limitations for certain 00:03:23.370 --> 00:03:26.490 other common infections. bronchitis and sinusitis? 00:03:26.590 --> 00:03:28.930 You did, and that's really important. For acute 00:03:28.930 --> 00:03:31.530 bacterial exacerbations of chronic bronchitis 00:03:31.530 --> 00:03:35.330 A, B, E, C, B, and also for acute bacterial sinusitis, 00:03:35.750 --> 00:03:38.669 the FDA guidance is now quite clear. Which is? 00:03:39.349 --> 00:03:42.289 Levofloxacin and fluoroquinolones generally should 00:03:42.289 --> 00:03:44.770 only be used for these conditions if there are 00:03:44.770 --> 00:03:47.210 no other appropriate antibiotic choices available. 00:03:48.259 --> 00:03:50.719 Why the restriction? It comes down to the risk 00:03:50.719 --> 00:03:52.259 of serious side effects, which we'll definitely 00:03:52.259 --> 00:03:55.000 get into more detail on later. Regulators decided 00:03:55.000 --> 00:03:57.419 the potential risks outweigh the benefits for 00:03:57.419 --> 00:04:00.340 these often self -limiting infections when other 00:04:00.340 --> 00:04:03.280 potentially safer options exist. It's that risk 00:04:03.280 --> 00:04:05.680 -benefit balance. That makes sense. A crucial 00:04:05.680 --> 00:04:09.500 calculation in medicine. I was also a bit surprised 00:04:09.500 --> 00:04:11.879 to see it listed for some really serious, maybe 00:04:11.879 --> 00:04:14.560 less common things. Yes, absolutely. It has a 00:04:14.560 --> 00:04:17.079 critical role in treating inhalational anthrax 00:04:17.079 --> 00:04:20.680 after exposure. That applies to both adults and 00:04:20.680 --> 00:04:23.639 kids, actually, down to six months old, though 00:04:23.639 --> 00:04:26.180 dosages differ based on weight. Anthrax, wow. 00:04:26.579 --> 00:04:28.819 And similarly, it's approved for treating plague 00:04:28.819 --> 00:04:31.639 both in the mnemonic and septicemic forms, and 00:04:31.639 --> 00:04:34.579 also for preventing plague after exposure, again 00:04:34.579 --> 00:04:38.209 in adult and children six months and up. So life 00:04:38.209 --> 00:04:40.470 -threatening situations, how do they even test 00:04:40.470 --> 00:04:42.550 efficacy for something like plague or anthrax? 00:04:42.629 --> 00:04:44.769 You can't exactly run standard human trials. 00:04:45.209 --> 00:04:47.329 Precisely. For ethical reasons, a lot of the 00:04:47.329 --> 00:04:49.350 efficacy data for these specific indications 00:04:49.350 --> 00:04:51.910 comes from animal studies. You extrapolate how 00:04:51.910 --> 00:04:54.189 well it works in controlled animal exposures 00:04:54.189 --> 00:04:57.149 to understand its likely benefit in humans. It's 00:04:57.149 --> 00:04:59.769 a necessary approach for these rare but potentially 00:04:59.769 --> 00:05:02.629 devastating diseases. Fascinating ethical navigation 00:05:02.629 --> 00:05:04.569 there. And it's also used for more common infections 00:05:04.569 --> 00:05:07.639 too, right? Like UTIs. Mm -hmm. Curinary tract 00:05:07.639 --> 00:05:10.279 infections, yes, including acute pylonephritis, 00:05:10.399 --> 00:05:13.259 which is a kidney infection specifically. And 00:05:13.259 --> 00:05:15.560 just as a side note, there's an eye drop formulation 00:05:15.560 --> 00:05:17.860 for bacterial conjunctivitis, you know, pink 00:05:17.860 --> 00:05:20.379 eye. Okay, so a real workhorse in some ways, 00:05:20.420 --> 00:05:22.639 but then there was this huge news I saw referenced 00:05:22.639 --> 00:05:26.100 regarding tuberculosis. That sounds potentially 00:05:26.100 --> 00:05:29.000 massive. It really is very significant. A major 00:05:29.000 --> 00:05:31.519 clinical trial results published just recently 00:05:31.519 --> 00:05:33.579 in the New England Journal of Medicine, January 00:05:33.579 --> 00:05:36.699 2025 it looks like, showed something pretty remarkable. 00:05:36.839 --> 00:05:39.079 What did they find? They found that a six month 00:05:39.230 --> 00:05:43.129 Once a day, oral regimen of levofloxacin significantly 00:05:43.129 --> 00:05:45.769 cut the risk of people developing drug -resistant 00:05:45.769 --> 00:05:48.550 TB. And even more impressively, it nearly halved 00:05:48.550 --> 00:05:51.129 the risk of developing multidrug -resistant TB, 00:05:51.410 --> 00:05:54.569 or MDR -TB. That applied to both adults and children. 00:05:54.889 --> 00:05:57.410 Halved the risk of MDR -TB? With a six -month 00:05:57.410 --> 00:05:59.610 oral course, that sounds like a game changer. 00:05:59.949 --> 00:06:03.180 It absolutely could be. Think about it. MDRTD 00:06:03.180 --> 00:06:05.600 treatment traditionally involves long, difficult 00:06:05.600 --> 00:06:08.339 regimens, sometimes two years or more, with toxic 00:06:08.339 --> 00:06:11.000 drugs and often lower success rates. A shorter, 00:06:11.360 --> 00:06:14.220 effective oral option like this. That could dramatically 00:06:14.220 --> 00:06:16.279 improve outcomes and make treatment feasible 00:06:16.279 --> 00:06:19.519 in many more settings globally. It's a huge potential 00:06:19.519 --> 00:06:21.339 step forward against a really tough disease. 00:06:21.620 --> 00:06:23.980 Wow. OK, so we know what it treats. Let's get 00:06:23.980 --> 00:06:27.180 into the how. How does levofloxacin actually 00:06:27.180 --> 00:06:29.899 stop these bacteria? What's the mechanism? So 00:06:29.899 --> 00:06:31.939 as we said, it's a It's a fluoroquinolone antibiotic. 00:06:32.300 --> 00:06:35.060 Its main job is to mess with two absolutely essential 00:06:35.060 --> 00:06:37.459 bacterial enzymes. They're called DNA gyrase 00:06:37.459 --> 00:06:40.100 and topoisomerase 3. Right. Enzymes involved 00:06:40.100 --> 00:06:42.459 in DNA. Exactly. Think of them as the bacteria's 00:06:42.459 --> 00:06:45.160 vital DNA toolkit managers. They're needed for 00:06:45.160 --> 00:06:47.360 basically everything DNA related. Copying the 00:06:47.360 --> 00:06:50.300 DNA, replication, reading the DNA to make proteins, 00:06:50.779 --> 00:06:53.279 transcription, repairing any damage, and rearranging 00:06:53.279 --> 00:06:56.399 bits of DNA. Recombination. All fundamental processes 00:06:56.399 --> 00:06:58.949 for the bacteria to survive and multiply. So 00:06:58.949 --> 00:07:01.709 levoflexis then jams those tools? Pretty much. 00:07:02.370 --> 00:07:04.750 By inhibiting these enzymes, it throws a major 00:07:04.750 --> 00:07:07.930 wrench into the works. The bacteria can't properly 00:07:07.930 --> 00:07:10.930 manage their DNA, vital processes grind to a 00:07:10.930 --> 00:07:13.449 halt, and ultimately the bacterial cell dies. 00:07:14.110 --> 00:07:16.470 It's a targeted strike at the core of their operations. 00:07:16.730 --> 00:07:18.550 OK, makes sense. So that's what the drug does 00:07:18.550 --> 00:07:20.990 to the bug. What about what our bodies do to 00:07:20.990 --> 00:07:23.660 the drug? the pharmacokinetics and pharmacodynamics. 00:07:24.199 --> 00:07:26.920 You described kinetics as body to drug and dynamics 00:07:26.920 --> 00:07:29.759 as drug to bug. That's a great way to remember, 00:07:29.920 --> 00:07:32.199 yes. Pharmacokinetics is all about absorption, 00:07:32.519 --> 00:07:35.379 distribution, metabolism, excretion. How the 00:07:35.379 --> 00:07:37.319 drug gets in, moves around, gets broken down, 00:07:37.339 --> 00:07:39.319 and gets out. And we have data on that, like 00:07:39.319 --> 00:07:42.240 CMAX, TMAX. Right. The FDA label gives us those 00:07:42.240 --> 00:07:45.160 key numbers. CMAX is the peak concentration the 00:07:45.160 --> 00:07:47.779 drug reaches in your blood. TMAX is how long 00:07:47.779 --> 00:07:50.879 it takes to hit that peak. AUC or... area under 00:07:50.879 --> 00:07:53.019 the curve, tells you the total drug exposure 00:07:53.019 --> 00:07:55.300 over time. And half -life is how long it takes 00:07:55.300 --> 00:07:57.699 for the concentration to drop by half. And these 00:07:57.699 --> 00:07:59.860 numbers change depending on how you take it. 00:08:00.000 --> 00:08:04.639 Pill, liquid, IV, and the dose. Exactly. A 750 00:08:04.639 --> 00:08:07.120 -milligram dose will generally give you a higher 00:08:07.120 --> 00:08:11.259 C -max and AUC than a 250 -milligram dose. An 00:08:11.259 --> 00:08:13.879 IV injection might reach its peak faster, a shorter 00:08:13.879 --> 00:08:17.160 T -max, than an oral tablet. And individual factors 00:08:17.160 --> 00:08:20.110 matter too. Things like your age, your gender, 00:08:20.449 --> 00:08:22.170 and especially how well your kidneys are working 00:08:22.170 --> 00:08:24.410 can influence these parameters. So doctors need 00:08:24.410 --> 00:08:26.649 to consider all that when dosing? Definitely. 00:08:27.009 --> 00:08:29.269 A higher C -max might be needed to quickly knock 00:08:29.269 --> 00:08:31.730 down a severe infection, while maybe a longer 00:08:31.730 --> 00:08:34.309 half -life is good for allowing once -daily dosing, 00:08:34.490 --> 00:08:36.389 which helps people stick to the treatment. It 00:08:36.389 --> 00:08:38.529 informs the strategy. What about distribution? 00:08:38.690 --> 00:08:40.830 I saw something about protein binding. Yeah, 00:08:40.870 --> 00:08:43.490 levofloxacin is about 30 % bound proteins in 00:08:43.490 --> 00:08:45.929 your blood plasma. That means the other 70 % 00:08:45.929 --> 00:08:48.610 or so is free, unbound, and available to travel 00:08:48.610 --> 00:08:50.509 into tissues and actually fight the bacteria. 00:08:50.850 --> 00:08:53.389 OK. And hydration is important, too. Very important. 00:08:54.090 --> 00:08:56.009 Levofloxacin is mainly cleared out by the kidneys 00:08:56.009 --> 00:08:58.470 into the urine. If you don't drink enough fluids, 00:08:58.629 --> 00:09:00.889 the urine can become too concentrated, and the 00:09:00.889 --> 00:09:02.889 drug might form tiny crystals. That's called 00:09:02.889 --> 00:09:05.500 crystalluria. It's potentially harmful to the 00:09:05.500 --> 00:09:08.419 kidneys, so staying well hydrated is key. Good 00:09:08.419 --> 00:09:11.580 practical tip. Now, those other terms, FC max 00:09:11.580 --> 00:09:16.070 MIC and FAUC24H MIC. Looks like alphabet soup. 00:09:16.350 --> 00:09:18.570 What do they tell us about effectiveness? Ah, 00:09:18.570 --> 00:09:22.009 yes. That gets into the pharmacodynamics, linking 00:09:22.009 --> 00:09:24.509 the drug concentration to its effect on the bacteria. 00:09:24.970 --> 00:09:27.809 MIC stands for Minimum Inhibitory Concentration. 00:09:28.169 --> 00:09:30.049 It's the lowest drug concentration needed to 00:09:30.049 --> 00:09:32.230 stop a specific bacterium from growing in a lab 00:09:32.230 --> 00:09:35.070 test. Okay. The minimum needed. Right. So FCMAX 00:09:35.070 --> 00:09:37.549 MIC compares the peak -free drug concentration. 00:09:37.710 --> 00:09:40.590 S means free, unbound drug, to that minimum requirement. 00:09:40.909 --> 00:09:43.429 It's like asking, was the initial hit strong 00:09:43.429 --> 00:09:46.789 enough compared to what's needed? An FAUC24H 00:09:46.789 --> 00:09:49.269 -MIC. That compares the total free drug exposure 00:09:49.269 --> 00:09:52.110 over a 24 -hour period to the MIC. It's more 00:09:52.110 --> 00:09:53.970 about sustained pressure. Was the drug level 00:09:53.970 --> 00:09:56.389 high enough or long enough over the day? So different 00:09:56.389 --> 00:09:58.169 measures of hitting the bacteria hard enough? 00:09:58.429 --> 00:10:01.440 Exactly. And for certain bugs... Like streptococcus 00:10:01.440 --> 00:10:03.820 pneumonia, which causes pneumonia, studies like 00:10:03.820 --> 00:10:06.620 one mentioned in Healthy Chinese Volunteers suggest 00:10:06.620 --> 00:10:08.779 you need to hit certain targets for these ratios 00:10:08.779 --> 00:10:11.659 to get the best clinical results. For example, 00:10:11.820 --> 00:10:16.740 maybe an FC max mech of 5 or more or an FAUC24HMIC 00:10:16.740 --> 00:10:19.620 of 30 or more seems to predict successful treatment. 00:10:20.039 --> 00:10:22.639 It helps determine optimal dosing regimens. That 00:10:22.639 --> 00:10:25.340 clarifies it nicely, thanks. So we understand 00:10:25.340 --> 00:10:27.500 how it works. How is it actually made? Where 00:10:27.500 --> 00:10:30.259 does Levaquin, the brand name, come from? Well, 00:10:30.259 --> 00:10:32.600 the information we have points to the Levaquin 00:10:32.600 --> 00:10:35.539 injection being manufactured for the OMP division 00:10:35.539 --> 00:10:37.720 of Orthomicneal Pharmaceutical, which is part 00:10:37.720 --> 00:10:40.179 of Johnson & Johnson, by Janssen Pharmaceutical 00:10:40.179 --> 00:10:43.259 and V located in Belgium. So manufactured in 00:10:43.259 --> 00:10:45.179 Belgium, a global product right from the start. 00:10:45.220 --> 00:10:47.320 Seems so. And it comes in different forms for 00:10:47.320 --> 00:10:49.840 hospital use, single use vials, premixed IV bags 00:10:49.840 --> 00:10:52.200 and flexible containers, various concentrations 00:10:52.200 --> 00:10:55.659 and volumes. but it needs careful handling, like 00:10:55.659 --> 00:10:58.159 storage at controlled room temperature and protection 00:10:58.159 --> 00:11:00.679 from light to maintain stability. And those patents 00:11:00.679 --> 00:11:02.600 we talked about earlier, like the European one, 00:11:02.679 --> 00:11:08.259 EP145 -1194b2, they describe the actual chemical 00:11:08.259 --> 00:11:11.480 steps involved. Precisely. They detail the how 00:11:11.480 --> 00:11:14.720 -to for making that specific levofloxacin hemihydrate 00:11:14.720 --> 00:11:17.720 form. There are also other patent entries, like 00:11:17.720 --> 00:11:20.019 one found via Google patents and another link 00:11:20.019 --> 00:11:25.360 on Patsnap Eureka from China, CN109721614a, related 00:11:25.360 --> 00:11:27.539 to preparation methods. What does that suggest? 00:11:27.679 --> 00:11:31.320 Ongoing tweaks. Generics. Could be both. It suggests 00:11:31.320 --> 00:11:33.500 ongoing work to maybe refine the process, make 00:11:33.500 --> 00:11:35.720 it more efficient, or perhaps reflects methods 00:11:35.720 --> 00:11:38.399 used by generic manufacturers after the original 00:11:38.399 --> 00:11:41.019 patents expired. The existence of generics is 00:11:41.019 --> 00:11:42.980 a big factor in its economic story, of course. 00:11:43.200 --> 00:11:45.340 Right. Which brings us squarely to maybe the 00:11:45.340 --> 00:11:48.639 most complex part of Levoflexation's story. The 00:11:48.639 --> 00:11:51.340 regulatory side, the legal issues, the controversies. 00:11:51.559 --> 00:11:53.399 It hasn't exactly been smooth sailing, has it? 00:11:53.500 --> 00:11:56.220 No, far from it. After that initial FDA approval 00:11:56.220 --> 00:11:59.220 in 1996, the subsequent years saw a steady drumbeat 00:11:59.220 --> 00:12:01.440 of safety concerns and increasingly strong warnings 00:12:01.440 --> 00:12:03.759 from regulatory bodies like the FDA, specifically 00:12:03.759 --> 00:12:06.000 about the entire fluoroquinolone class, which 00:12:06.000 --> 00:12:08.259 includes labofloxanes. What triggered these? 00:12:08.340 --> 00:12:11.120 What were the first major flags? The first really 00:12:11.120 --> 00:12:15.340 big one was about tendons. In July 2008, the 00:12:15.340 --> 00:12:18.080 FDA mandated a boxed warning. That's their most 00:12:18.080 --> 00:12:20.659 serious type of warning, highlighting an increased 00:12:20.659 --> 00:12:23.879 risk of tendonitis and, more worryingly, tendon 00:12:23.879 --> 00:12:26.759 rupture. Tendon rupture? That sounds serious. 00:12:26.919 --> 00:12:29.360 It is. Especially concerning the Achilles tendon, 00:12:29.440 --> 00:12:32.139 but others too. This risk was found to be higher 00:12:32.139 --> 00:12:34.779 in older patients, those taking corticosteroids, 00:12:35.120 --> 00:12:37.200 and transplant recipients. And the warnings didn't 00:12:37.200 --> 00:12:40.500 stop there? No. In February 2011, the boxed warning 00:12:40.500 --> 00:12:43.179 was updated again. This time, it added the risk 00:12:43.179 --> 00:12:45.500 of making muscle weakness worse in people who 00:12:45.500 --> 00:12:48.159 already have myasthenia gravis, which is a neuromuscular 00:12:48.159 --> 00:12:50.980 disorder. Okay, so tendons, then myasthenia gravis. 00:12:51.059 --> 00:12:54.809 What came next? Nerves. In August 2013, the FDA 00:12:54.809 --> 00:12:57.149 required label updates about the potential for 00:12:57.149 --> 00:12:59.509 irreversible peripheral neuropathy. Irreversible 00:12:59.509 --> 00:13:02.230 nerve damage? Yes. Symptoms like pain, burning, 00:13:02.649 --> 00:13:05.490 tingling, numbness, weakness, potentially starting 00:13:05.490 --> 00:13:07.570 soon after beginning the drug and possibly becoming 00:13:07.570 --> 00:13:09.950 permanent. That was another major red flag about 00:13:09.950 --> 00:13:12.389 potentially long -lasting harm. That's a cascade 00:13:12.389 --> 00:13:15.289 of serious warnings. Then there was an FDA meeting 00:13:15.289 --> 00:13:18.029 specifically about its use for common infections. 00:13:18.350 --> 00:13:22.190 Exactly. In November 2015, an FDA advisory committee 00:13:22.190 --> 00:13:25.120 met. They specifically looked at using fluoroquinolones 00:13:25.120 --> 00:13:28.600 for acute sinusitis, acute bronchitis exacerbations, 00:13:29.200 --> 00:13:33.039 and uncomplicated UTIs. The concern was the growing 00:13:33.039 --> 00:13:35.620 number of reports about multiple, disabling, 00:13:35.820 --> 00:13:37.659 and potentially permanent side effects happening 00:13:37.659 --> 00:13:40.620 together, affecting tendons, muscles, joints, 00:13:40.919 --> 00:13:43.480 nerves, and the central nervous system. And what 00:13:43.480 --> 00:13:46.080 did the committee conclude? They basically concluded 00:13:46.080 --> 00:13:48.379 that for these less serious infections, where 00:13:48.379 --> 00:13:50.600 other treatment options are available, the serious 00:13:50.600 --> 00:13:53.259 risks associated with fluoroquinolones generally 00:13:53.259 --> 00:13:55.419 outweighed the benefits for most patients. That 00:13:55.419 --> 00:13:57.419 feels like a real turning point in how the drug 00:13:57.419 --> 00:14:00.139 was viewed. It was. And it led directly to stronger 00:14:00.139 --> 00:14:03.559 actions. In July 2016, the FDA approved even 00:14:03.559 --> 00:14:05.840 stronger warnings, emphasizing these disabling 00:14:05.840 --> 00:14:08.419 and potentially permanent side effects. The recommendation 00:14:08.419 --> 00:14:11.360 became reserved fluoroclonal loans for patients 00:14:11.360 --> 00:14:13.220 with these common infections who have no other 00:14:13.220 --> 00:14:15.679 treatment options. Limit their use drastically 00:14:15.679 --> 00:14:17.679 in these situations. And Europe followed suit. 00:14:18.100 --> 00:14:20.799 Yes. The European Medicines Agency, the EMA, 00:14:21.240 --> 00:14:23.059 conducted its own review around the same time. 00:14:23.200 --> 00:14:25.700 They also came out with new restrictions or precautions 00:14:25.700 --> 00:14:29.720 due to, as they put it, very rare but disabling 00:14:29.720 --> 00:14:32.940 long -lasting or irreversible side effects, primarily 00:14:32.940 --> 00:14:35.559 involving the musculoskeletal and nervous systems, 00:14:36.080 --> 00:14:38.659 but also psychiatric issues and sensory problems. 00:14:39.580 --> 00:14:41.899 So a transatlantic consensus was emerging about 00:14:41.899 --> 00:14:44.610 significant risks. With all these warnings piling 00:14:44.610 --> 00:14:47.090 up, it's probably not surprising that legal action 00:14:47.090 --> 00:14:49.649 followed. Not surprising at all. Thousands of 00:14:49.649 --> 00:14:51.549 lawsuits have been filed against the manufacturers, 00:14:51.809 --> 00:14:54.690 companies like Bayer, Merck, Johnson & Johnson 00:14:54.690 --> 00:14:57.350 subsidiaries. What was the main argument in these 00:14:57.350 --> 00:15:00.509 lawsuits? The core allegation typically was failure 00:15:00.509 --> 00:15:03.149 to adequately warn. Plaintiffs argued that the 00:15:03.149 --> 00:15:05.470 companies knew or should have known about these 00:15:05.470 --> 00:15:07.990 serious risks sooner and didn't properly inform 00:15:07.990 --> 00:15:09.710 doctors and patients through the drugs labeling. 00:15:09.850 --> 00:15:12.730 So claims like negligence, failure to warn. Yes, 00:15:12.889 --> 00:15:15.429 those were common claims. Negligence in testing 00:15:15.429 --> 00:15:17.789 or labeling, strict liability, arguing the drug 00:15:17.789 --> 00:15:20.769 was inherently defective or unreasonably dangerous, 00:15:20.889 --> 00:15:23.490 and sometimes even fraud, alleging intentional 00:15:23.490 --> 00:15:26.629 downplaying of the risks. Did the focus of these 00:15:26.629 --> 00:15:29.889 lawsuits change as the FDA warnings evolved? 00:15:30.470 --> 00:15:33.190 Absolutely. You can track it. Early on, many 00:15:33.190 --> 00:15:35.809 lawsuits centered on tendonitis and tendon ruptures, 00:15:36.350 --> 00:15:39.149 matching that first 2008 boxed warning. Makes 00:15:39.149 --> 00:15:42.330 sense. Then, after the 2013 warning about peripheral 00:15:42.330 --> 00:15:45.129 neuropathy, that became a major focus of litigation. 00:15:45.769 --> 00:15:48.529 Nerve damage claims surged. And more recently? 00:15:48.970 --> 00:15:51.470 More recently, especially after general FDA warnings 00:15:51.470 --> 00:15:54.590 in 2018 about fluoroquinolones and the risk of 00:15:54.590 --> 00:15:57.289 aortic aneurysms and aortic dissections basically, 00:15:57.889 --> 00:15:59.789 dangerous bulging or tearing in the body's main 00:15:59.789 --> 00:16:02.669 artery. Those severe cardiovascular events have 00:16:02.669 --> 00:16:05.409 become a growing area in the lawsuits. Again, 00:16:05.509 --> 00:16:07.970 often with the claim that manufacturers had signals 00:16:07.970 --> 00:16:09.990 about these risks earlier than they disclose 00:16:09.990 --> 00:16:12.529 them fully. It paints a picture of a powerful 00:16:12.529 --> 00:16:15.269 drug, undoubtedly useful, but one where the understanding 00:16:15.269 --> 00:16:17.789 of its potential downsides has grown significantly 00:16:17.789 --> 00:16:20.769 over time. That's exactly it. The risk -benefit 00:16:20.769 --> 00:16:23.389 calculation has shifted dramatically, especially 00:16:23.389 --> 00:16:26.169 for those less severe infections. The clear message 00:16:26.169 --> 00:16:30.129 now is caution and reserving these drugs for 00:16:30.129 --> 00:16:33.509 situations where they are truly necessary and 00:16:33.509 --> 00:16:35.929 the benefits clearly outweigh these now well 00:16:35.929 --> 00:16:38.659 -documented risks. And communication channels 00:16:38.659 --> 00:16:42.320 like the FDA's MedWatch system or reports from 00:16:42.320 --> 00:16:44.700 places like CIDRAP at the University of Minnesota, 00:16:45.259 --> 00:16:47.279 they're crucial for getting this safety info 00:16:47.279 --> 00:16:49.720 out. Absolutely critical. Getting these updates 00:16:49.720 --> 00:16:52.080 to doctors and pharmacists on the front lines 00:16:52.080 --> 00:16:54.460 is essential for changing prescribing practices 00:16:54.460 --> 00:16:56.879 and protecting patients. This whole regulatory 00:16:56.879 --> 00:16:59.539 and legal saga must have had economic consequences, 00:16:59.820 --> 00:17:01.970 too. Oh, certainly. On the one hand, the arrival 00:17:01.970 --> 00:17:04.609 of generic levofloxacin after the patents expired 00:17:04.609 --> 00:17:06.430 would have driven down the price significantly 00:17:06.430 --> 00:17:09.150 compared to the brand name Levon. That's standard 00:17:09.150 --> 00:17:11.470 market dynamics. But the warnings probably dampen 00:17:11.470 --> 00:17:14.490 demand. Exactly. Studies have looked at prescribing 00:17:14.490 --> 00:17:17.869 patterns before and after these major FDA warnings, 00:17:18.230 --> 00:17:20.509 and they generally show a noticeable decrease 00:17:20.509 --> 00:17:23.269 in fluoroquinolone use, particularly for those 00:17:23.269 --> 00:17:25.430 infections where they are no longer recommended 00:17:25.430 --> 00:17:28.160 as first -line therapy. That directly hits market 00:17:28.160 --> 00:17:30.519 share and revenue. And this ties into a bigger 00:17:30.519 --> 00:17:32.720 issue in the antibiotic world, doesn't it? The 00:17:32.720 --> 00:17:35.859 pipeline for new drugs. It does. Experts like 00:17:35.859 --> 00:17:38.039 Dr. Brad Spellberg have been quite vocal about 00:17:38.039 --> 00:17:40.900 this. There's a real concern that large pharmaceutical 00:17:40.900 --> 00:17:43.000 companies are pulling back from antibiotic R 00:17:43.000 --> 00:17:46.579 &D. Why is that? It's a tough combination. The 00:17:46.579 --> 00:17:49.200 science itself is difficult. Discovering genuinely 00:17:49.200 --> 00:17:53.140 new classes of antibiotics is hard. The economics 00:17:53.140 --> 00:17:55.799 aren't great. Antibiotics are typically taken 00:17:55.799 --> 00:17:58.599 for short periods, unlike chronic disease meds, 00:17:58.819 --> 00:18:00.880 and resistance can shorten their lifespan, making 00:18:00.880 --> 00:18:04.599 it hard to recoup massive R &D costs. Plus, some 00:18:04.599 --> 00:18:06.619 argue the regulatory environment, while necessary 00:18:06.619 --> 00:18:09.119 for safety, can also be challenging for developers. 00:18:09.640 --> 00:18:11.799 So companies might see it as less profitable 00:18:11.799 --> 00:18:14.440 than other areas. That seems to be the case. 00:18:14.900 --> 00:18:17.319 When a major player like Pfizer significantly 00:18:17.319 --> 00:18:19.960 scales back its antibiotic research, as happened 00:18:19.960 --> 00:18:22.500 a few years ago, it sends a worrying signal. 00:18:22.559 --> 00:18:25.539 We desperately need new antibiotics to combat 00:18:25.539 --> 00:18:28.420 resistance, but the current market doesn't always 00:18:28.420 --> 00:18:31.099 incentivize their development effectively. It's 00:18:31.099 --> 00:18:33.480 a real public health challenge. A very sobering 00:18:33.480 --> 00:18:36.019 point. Okay, lastly, let's think about the cultural 00:18:36.019 --> 00:18:39.460 impact. How has levofloxacin and the broader 00:18:39.460 --> 00:18:41.960 story of antibiotics and resistance influenced 00:18:41.960 --> 00:18:44.400 public perception and behavior? Well, there's 00:18:44.400 --> 00:18:46.579 definitely increased awareness, partly thanks 00:18:46.579 --> 00:18:49.220 to campaigns like the WHO's Global Action Plan 00:18:49.220 --> 00:18:51.779 on antimicrobial resistance. People hear more 00:18:51.779 --> 00:18:54.279 about superbugs. But understanding is still patchy. 00:18:54.380 --> 00:18:57.900 Very much so. WHO surveys across different countries 00:18:57.900 --> 00:19:00.859 consistently show significant public misunderstanding. 00:19:01.400 --> 00:19:03.579 For instance, lots of people still think antibiotics 00:19:03.579 --> 00:19:05.680 work against colds and flu, which are viral, 00:19:05.720 --> 00:19:08.039 of course. And a worrying number believe you 00:19:08.039 --> 00:19:10.059 should stop taking antibiotics as soon as you 00:19:10.059 --> 00:19:12.640 feel better rather than completing the full course. 00:19:13.319 --> 00:19:15.420 These kinds of beliefs directly contribute to 00:19:15.420 --> 00:19:17.859 the rise of resistance, which undermines the 00:19:17.859 --> 00:19:20.420 effectiveness of drugs like levofloxacin. for 00:19:20.420 --> 00:19:22.839 everyone. And the safety warnings and lawsuits 00:19:22.839 --> 00:19:25.500 we discuss that must also shape how people view 00:19:25.500 --> 00:19:28.039 these drugs. Unquestionably. The media coverage 00:19:28.039 --> 00:19:30.440 around tendon ruptures, nerve damage, and other 00:19:30.440 --> 00:19:32.779 serious side effects associated with fluoroquinolones 00:19:32.779 --> 00:19:36.119 has likely created a sense of caution, maybe 00:19:36.119 --> 00:19:38.960 even fear, among some patients and prescribers. 00:19:39.420 --> 00:19:41.359 It becomes part of the narrative around these 00:19:41.359 --> 00:19:44.819 drugs. So it's this complex picture, a drug that's 00:19:44.819 --> 00:19:47.140 vital for treating really dangerous infections 00:19:47.140 --> 00:19:50.460 like MDRTB or anthrax. Absolutely critical in 00:19:50.460 --> 00:19:52.619 those cases. But also one that carries significant 00:19:52.619 --> 00:19:54.980 risks and is now advised against for more common 00:19:54.980 --> 00:19:57.440 ailments, all playing out against this backdrop 00:19:57.440 --> 00:20:00.140 of growing resistance and public confusion. It 00:20:00.140 --> 00:20:02.299 really encapsulates the double -edged sword of 00:20:02.299 --> 00:20:05.440 powerful medicines. Essential, but requiring 00:20:05.440 --> 00:20:08.799 careful, informed use and ongoing vigilance. 00:20:09.500 --> 00:20:12.420 It highlights the need for really clear communication 00:20:12.420 --> 00:20:15.960 between doctors and patients about why an antibiotic 00:20:15.960 --> 00:20:18.819 is needed or why perhaps it isn't and what the 00:20:18.819 --> 00:20:20.859 potential downsides are. So wrapping up our deep 00:20:20.859 --> 00:20:23.839 dive on levofloxacin, we've traced its path from 00:20:23.839 --> 00:20:26.779 discovery and patenting. Explored its wide range 00:20:26.779 --> 00:20:29.759 of uses, from common UTIs to life -threatening 00:20:29.759 --> 00:20:32.839 plague and its potential new role in TB. delved 00:20:32.839 --> 00:20:35.960 into how it works at the molecular level, disrupting 00:20:35.960 --> 00:20:38.259 bacterial DNA. Looked at how it's made, how our 00:20:38.259 --> 00:20:40.140 bodies handle it, and what makes it effective. 00:20:40.339 --> 00:20:42.799 And spent significant time on the really crucial 00:20:42.799 --> 00:20:45.700 regulatory story, the warnings, the lawsuits, 00:20:46.039 --> 00:20:48.079 the shifting understanding of its risks. Which 00:20:48.079 --> 00:20:50.220 in turn have shaped its economic life and its 00:20:50.220 --> 00:20:52.319 cultural perception tied into the larger story 00:20:52.319 --> 00:20:54.819 of antibiotic resistance. It really shows that 00:20:54.819 --> 00:20:56.980 even a single drug can have such an intricate 00:20:56.980 --> 00:20:59.640 history and ongoing impact. Definitely not just 00:20:59.640 --> 00:21:02.539 a simple pill. It underscores that constant balancing 00:21:02.539 --> 00:21:04.799 act in medicine weighing the profound benefits 00:21:04.799 --> 00:21:07.579 against the potential harms. And it really brings 00:21:07.579 --> 00:21:09.839 home the importance of using these precious resources 00:21:09.839 --> 00:21:13.099 wisely. Maybe prompts you, the listener, to think 00:21:13.099 --> 00:21:15.859 about antibiotic stewardship and perhaps check 00:21:15.859 --> 00:21:19.619 out some resources, like from the WHO on antimicrobial 00:21:19.619 --> 00:21:21.920 resistance. Yeah, and it leaves us with a critical 00:21:21.920 --> 00:21:25.390 question to ponder. With potent tools like levofloxan 00:21:25.390 --> 00:21:28.369 that can save lives, but also cause harm How 00:21:28.369 --> 00:21:30.470 do we collectively the medical world and all 00:21:30.470 --> 00:21:32.670 of us as individuals ensure we're using them 00:21:32.670 --> 00:21:35.049 in the best possible way? How do we maximize 00:21:35.049 --> 00:21:36.890 the good minimize the bad and preserve their 00:21:36.890 --> 00:21:39.369 power for the future when we'll undoubtedly still 00:21:39.369 --> 00:21:39.809 need them?